Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02701127 · ClinicalTrials.gov registry record · Early Phase 1
Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury
A Early Phase 1 study of Acute Kidney Injury, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT02701127 is a Early Phase 1 study of Acute Kidney Injury that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 55 participants, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02701127, a Early Phase 1 study of Acute Kidney Injury, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, randomized, single-blind, placebo-controlled study to evaluate the safety and biochemical effects of niacinamide on metabolic parameters of the kidney in patients undergoing cardiac surgery.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oral niacinamide, 1 gram daily
- DRUG Oral niacinamide, 3 gram daily
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02701127
The ClinicalTrials.gov registry entry for NCT02701127 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,330-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (98% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02701127 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02701127 about?
NCT02701127 is a clinical study titled "Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury". This is a single center, randomized, single-blind, placebo-controlled study to evaluate the safety and biochemical effects of niacinamide on metabolic parameters of the kidney in patients undergoing cardiac surgery.
What is the current status of trial NCT02701127?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 55 participants. The study started on 2016-03. Estimated completion is 2017-07.
What conditions does trial NCT02701127 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT02701127?
The interventions under investigation include: Placebo (DRUG), Oral niacinamide, 1 gram daily (DRUG), Oral niacinamide, 3 gram daily (DRUG).
Who is sponsoring clinical trial NCT02701127?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02701127 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.